Skip to main content
Caplight Logo









xCures

xCures

Private
Oakland, CaliforniaHealthcare & Life Scienceshttps://xcures.com/

Last Round

Series B

Jun 24, 2026

Est. Valuation

$127M

Total Funding Raised

$61.09M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

xCures is a healthcare technology company that operates an AI-assisted platform to aggregate, normalize, and structure fragmented medical records into a searchable database for clinical insights.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Healthcare Analytics, Biotechnology, Data Integration

Business Model

B2B

Customer Profile

Usage-Based SaaS, Subscription SaaS

AI Layer

Application

Keywords

real-world evidenceRWEreal-world dataclinical trial matchingRWDclinical data aggregationclinical trial softwareoncology researchEHR integrationclinical data platformpatient access serviceshealth data interoperabilityTEFCAclinical trial recruitmenthealthcare SaaSdata normalization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

xCures Comparables

Compare xCures with similar companies based on industry and business-model similarity.

xCures comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ensemble Health Partners
83%
Verana Health
83%
ConcertAI
81%

xCures Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 24, 2026
Series AJun 23, 2021
Convertible DebtAug 19, 2020

Key People

Founding team and executive leadership

Mika Newton

Chief Executive Officer

Executive Team

Glenn Kramer

Chief Technology Officer

Executive Team

xCures Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 16, 2026

    Grew 22% QoQ, from 58 to 71 employees.

  • Jul 27, 2026

    Grew 37% QoQ, from 51 to 70 employees.

Recent news

Latest coverage and updates

  • receives_financingJun 24, 2026

    xCures, Inc. received financing of $46M in Series B on Jun 24th '26.

xCures Filings

Explore SEC and related filing metadata, where available.

xCures filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about xCures's valuation, stock price, and market status.

Is xCures a public or private company?

xCures is a private company.

What is the current stock price of xCures?

xCures is a private company with no public stock price. No recent secondary market data is available.

How much is xCures worth (valuation)?

xCures's valuation is estimated at $127.0M based on funding round data.

Can I buy xCures stock?

xCures shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was xCures's last funding round?

xCures's most recent funding round was Series B on June 24, 2026.

Who are the main investors in xCures?

Key investors in xCures include Innovius Capital, Boehringer Ingelheim Venture Fund.

Will xCures IPO soon?

No public IPO plans have been announced for xCures.

How can I track xCures secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor xCures's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOakland, California
Employee Range57
Year Founded2018
Last FundingJun 24, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?